Skip to main content

Table 3 Overall outcomes from treatment with 2-year event rates showing differences between SUV max categories

From: Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy

   

SUVmax < 5

SUVmax ≥ 5

 
 

2-year freedom from event (%)

Total events n (%)

2-year freedom (%)

2-year freedom (%)

K-M p

Local failure

93.7

8 (8.4)

97

86

.256

Regional failure

90.5

10 (10.5)

94

82

.131

Distant failure

86.3

15 (15.8)

91

78

.371

Any progression

93.7

25 (26.3)

88

62

.024

Death

64.2

48 (50.5)

72

49

.024

  1. Comparison of SUVmax categories shows a statistically significant difference in progression-free and overall survivals.